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Background: The relevance of Trichosporon species for cystic fibrosis (CF) patients has not yet been extensively
investigated.
Methods: The clinical course of CF patients with Trichosporon spp. in their respiratory secretions was analysed
between 2003 and 2010 in the Munich CF center. All respiratory samples of 360 CF patients (0 – 52.4 years; mean
FEV1 2010 81.4% pred) were investigated.
Results: In 8 patients (2.2%, 3 male, mean age 21.8 years) Trichosporon was detected at least once. One patient
carried T. asahii. One patient carried T. mycotoxinivorans and one patient T. inkin as determined by DNA sequencing.
As potential risk factors for Trichosporon colonization steroid treatment, allergic bronchopulmonary aspergillosis (ABPA)
and CF associated diabetes were identified in 6, 5, and 2 patients respectively. For one patient, the observation period
was not long enough to determine the clinical course. One patient had only a single positive specimen and exhibited
a stable clinical course determined by change in forced expiratory volume in one second (FEV1), body-mass-index
(BMI), C-reactive protein (CRP) and immunoglobulin G (IgG). Of 6 patients with repeatedly positive specimen (mean
detection period 4.5 years), 4 patients had a greater decline in FEV1 than expected, 2 of these a decline in BMI and 1
an increase in IgG above the reference range. 2 patients received antimycotic treatment: one patient with a tormenting
dry cough subjectively improved under Amphotericin B inhalation; one patient with a severe exacerbation due to
T. inkin was treated with i.v. Amphotericin B, oral Voriconazole and Posaconazole which stabilized the clinical condition.
Conclusions: This study demonstrates the potential association of Trichosporon spp. with severe exacerbations in
CF patients.
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Trichosporon species (T. spp.) belong to the genus of
basidiomycetous yeast and are widely distributed in
nature. They are found in soil and water and are
known to colonize skin and gastrointestinal tract of
humans [1,2]. Numerous Trichosporon spp. have been
characterized [3], while only a few cause human* Correspondence: matthias.griese@med.uni-muenchen.de
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reproduction in any medium, provided the ordisease including T. asahii, T. inkin, T. asteroides, T.
cutaneum, T. mucoides, T. ovoides (formerly subsumed
as a single species: T. beigelii [4,5]) and two more recently
described species: T. louberi and japonicum [6]. The most
relevant disease entities caused by Trichosporon spp. are
white piedra, a mycosis of the hair (T. inkin, T. ovoides)
[4], summer-type hypersensitivity pneumonitis in Japan
(T. asahii, T. mucoides and T. dermatis) [4] and invasive
trichosporonosis (local and disseminated; most often
caused by T. asahii) [4]. Risk factors for invasive trichos-
poronosis are immunosuppression, including prolonged
corticosteroid treatment, impaired granulocyte function,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease, extensive burns and HIV [7,8]. Invasive Tri-
chosporon infections are the second most common
yeast fungaemia in humans [4,9], especially in patients
with haematological malignancies [10]. Symptoms of
invasive trichosporonosis range from pulmonary infiltrates,
skin lesions and renal failure to local organ infections,
such as hepatitis [4].
The significance of Trichosporon spp. for CF patients
has so far not been widely recognized. Only three case
reports are available in literature: One 11-year old CF
patient suffered from a non-aspergillus allergic broncho-
pulmonary mycosis due to T. beigelii and recovered
within 2 months under intensive steroid and antifungal
therapy [11]. One 20-year old, male CF patient died
within a few days from admission due to a fulminant
pneumonia with T. mycotoxinivorans [12] and one 35-
year old CF patient died due to a disseminated fatal
infection with T. mycotoxinivorans 29 days after lung
transplantation [13]. Aim of this study was to investigate
the detection rate of Trichosporon spp. in a German CF
cohort and to describe the clinical course of patients
positive for Trichosporon.
Methods
All respiratory samples of 360 CF patients (mean age
2010 18.11 years, range 0 – 52.4; mean FEV1 81.4% pred;
range 16 – 136% pred; 12.5% with associated diabetes
mellitus) who attended the CF Center at the Children’s
University Hospital in Munich were studied between
January 1st, 2003 and December 31st, 2010 for the
presence of bacterial and/or fungal pathogens. Other
detected fungi included Aspergillus species (approximately
16% of the cohort, >90% Aspergillus fumigatus) and
Candida species (approximately 40% of the cohort, >90%
Candida albicans). 15% of the patients exhibited intermit-
tent Pseudomonas aeruginosa colonization, 48% chronic
colonization. Patient visits took place on average every
three months, if indicated more often. At each visit,
sputum samples or throat smears were taken and the
patients were investigated clinically; routine laboratory
examinations including inflammatory parameters and
lung-function tests were performed. On average 4 respira-
tory samples/patient/year were analysed, approximately
70% of the samples were throat swabs, 30% expectorated
sputum. The clinical course of Trichosporon positive
patients was analysed retrospectively based on forced
expiratory volume in one second (FEV1,%pred), body
mass index (BMI) and the inflammatory markers CRP
(mg/l) and immunoglobulin G (IgG, g/l), the latter known
to be associated with chronic inflammation and inversely
correlated with lung function and long-term prognosis
[14,15]. The erythrocyte sedimentation rate 1 h (ESR,
mm) was also recorded; however, insufficient data wasavailable for analysis. Decline in FEV1 was defined as a
drop of the yearly mean FEV1 of >1%pred/year from
first detection to the end of the observation period of
the individual patient, based on the average yearly drop
of FEV1 values of 1% in large CF registries [16]. Any
change in BMI was recorded, increase in CRP was defined
as an increase by >5 mg/l and an increase in IgG was
defined as an increase by >3 g/l from first detection to
the end of the observation period. Informed consent
was obtained from all participants and the study was
approved by the institutional review board of the Univer-
sity of Munich.
Specimen characterization
Microbiological examinations were routinely performed
at the department of microbiology at the Dr. von Hauner
Children’s hospital in Munich. Specimen with newly
identified microorganisms were also analysed at the
Max von Pettenkofer-Institute in Munich (National Con-
siliary Laboratory for CF Bacteriology, South Germany).
Clinical specimens were diluted 1:2 with Dithiothreitol
(DTT; Sigma, Deisenhofen, Germany) solution (1 mg/ml)
for liquefaction. For quantitative bacteriology sputum
samples were diluted 10-1, 10-4 and 10-5 with 0,9% NaCl
and plated on Trypticase soy agar (TSA) and McConkey
Agar. DTT-pretreated samples were further streaked on
Columbia Agar with 5% sheep blood, Chocolate agar,
Sabouraud-Glucose-Agar for fungi as well as on selective
media containing either 8 μg/ml Meropenem or 16 μg/ml
Polymyxin B to recover Carbapenem-resistent gram-
negative bacteria and Burkholderia cepacia complex
isolates, respectively. Columbia Agar and Chocolate
agar were incubated at 32°C under anaerobic condi-
tions to prevent overgrowth of clinically important bac-
teria such as H. influenza by P. aeruginosa, while all
other media were incubated aerobically at 32°C. All
bacteriological cultures were incubated for 3–5 days
and Sabouraud-Glucose-Agar for at least 10 days. Species
identification was performed by routine microbiological
procedures. Yeasts were isolated on chromogenic Agar
plates for differentiation. Filamentous fungi were primarily
differentiated by micromorphological examinations.
Trichosporon spp. in pts 1,2,4,6,7,8 were identified by
alternative biochemical test (API 20 C AUX and ID 32
C galleries bioMérieux, Mercy l’Etoile, France). T. asahii
(patient 2) was identified by microscopic identification,
biochemical testing and Matrix Assisted Laser Desorption
Ionisation – Time of flight Mass Spectrometry (MALDI-
TOF MS Biotyper system Bruker Daltonics). Three strains
(two strains of patient 3, one strain of patient 5) were
further analysed - prompted by the clinical deterioration
of these patients after Trichosporon detection. In a first
step these strains were identified by the MALDI-TOF MS
BioTyper system; in a second step DNA sequencing was
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TOF MS is a reliable method to rapidly identify fungal
species, and can be used as an alternative to PCR-based
techniques [17,18], which have been extensively used
for the identification of Trichosporon spp. [19]. DNA
sequencing of conserved (D1/D2 region of the 28S rDNA)
and variable regions (ITS and IGS1 regions) are common
methods to determine Trichosporon spp. [20,21].
In this study the detected mass spectra in the MALDI-
TOF analysis of the two patients 3 and 5 (scores >1.700)
were compared to the reference spectra of Trichosporon
spp. included in the MALDO Biotyper BDAL MSP library.
The results were confirmed by DNA sequencing: Parts
of the 28S rDNA were sequenced and compared with
fungal consensus sequences of Trichosporon spp. in the
NCBI BLASTW. Parts of the 28S rDNA region were
amplified by PCR using the following oligonucleotide
primers: primer P1( 45–64): 5’-ATCAATAAGCGGAG
GAAAAG-3’ and primer P2 (825–843): 5’-CTCTGG
CTTCACCCTATTC-3’. The identity of sequenced strains
was 99.0% for T. inkin and T. mycotoxinivorans re-
spectively. Figure 1 demonstrates the discrimination
between the sequenced isolates and the most common
Trichosporon spp. Due to varying lengths of publishedPatient 5
Figure 1 Phylogenetic tree of Trichosporon spp (28S rDNA). Discrimina
2010 and one from 2012) and of patient 5 and the most common Trichosp
used to realize alignment, performed by MegAlign, software version 8.1.4, L
branch lengths and represents the number of substitutions per 100 residuesequences (500 to 1000 bp) a comparable sequence
length of 562 bp was used to realize the alignment per-
formed by MegAlign, software version 8.1.4, Lasergene,
DNASTARW.Results
Trichosporon spp. were detected in 8 of 360 patients (i.e.
2.2%; 3 male; mean age: 21.8 years, range: 8 – 41.1; Table 1).
Two Trichosporon spp. were specified by MALDI-TOF MS
and by DNA sequencing: T. mycotoxinivorans and T.
inkin. T. asahii was identified by microscopy, biochemical
testing and MALDI-TOF MS. All but one patient were
colonized with further CF typical microorganisms at first
detection as depicted in Table 1. 5 patients had a history
of ABPA 0–5 years prior to first detection. 5 patients
had a history of treatment with nebulized steroids and/
or steroid inhalers, 3 of whom had received additional
systemic steroid treatment, one patient had received
systemic steroid treatment only. 2 patients had CF associ-
ated diabetes at first detection. No patient underwent lung
transplantation. All 8 patients had a dF508 mutation, 3
patients an additional stop mutation (2 patients R553X
and one patient S466X) (Table 1).Patient 3
Patient 3
tion between the sequenced isolates of patient 3 (one isolate from
oron spp (NCBI Blast). A comparable sequence length of 562 bp was
asergene, DNASTAR. The bar shown in the graph provides scale to the
s.
Table 1 Characterization and follow-up of CF patients positive for Trichosporon
Patient number 1 2 3 4 5 6 7 8
Sex F M F M F F M F
Mutation dF508/ dF508 dF508/ dF508 dF508/ Nk dF508/ R553X dF508/ S466X dF508/ Nk dF508/ Nk dF508/ R553X
Age at first detection (y) 41.1 33.0 10.0 11.0 21.7 8.0 22.3 27.6
Age at last detection (y) 43.0 36.9 17.8 11.0 28.4 8.6 29.2 28.4
Follow up (y)* 3.1 5.9 7.8 2.4 6.7 5.3 6.9 0.8
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Pseudoall boyd (rep), Cand
glab (rep), Cand alb (rep),
Cand paraps (rep), Enteroc
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Inqu lin (rep), Burc
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prior to first detection
(agent; regimen)
Oral Cip (cont) Cefur (cont),
Cip (2 w on/off)
Cep (cont),
Cip (2 w on/off)
Ceph (cont),
Cip (2 w on/off)
Ceph (cont) Ceph (cont), cip (2
w on/off)
Ceph (cont) Cot (cont)
Inhaled Tob/col (2 w on/off) None Col (2 w on/off) Tob/col (2 w on/off) Gern (2 w on/off) None Gern (2 w on/off) Gern/col
(2 w on/off)
iv (courses/y) 2 2 1 1 2 1 1 2
Diabetes mellitus
(at first detection)
Yes Yes no No No No No No
ABPA (years prior
to first detection)
5y, 2y 3y no 3y, 1y No 1 y after first
detection
No At first detection
Nebulized/inhaled
steroids prior to first
detection (duration)





Yes Yes No Yes Yes No No Yes (from first
detection on)
Lung function
FEV 1 (% pred)**
Decline Stable Decline Increase Decline Increase Decline Np
At first detection 61.2 49.3 81.2 84.3 86.3 68.2 40.1 61.3
At end of observation 43.1 47.2 57.3 88.3 79.0 79.6 30.0 Np
BMI (kg/m2)*** Decline Stable Increase Increase Increase Increase Decline Np
At first detection 18.9 25.8 13.7 15.5 19.6 15.1 19.3 21.5
At end of observation 18.2 25.8 17.8 16.3 19.9 18 18.5 Np




















Table 1 Characterization and follow-up of CF patients positive for Trichosporon (Continued)
At first detection 18.8 13.0 8.1 8.2 10.4 9.5 13.4 9.2
At end of observation 22.4 13.7 13.1 10.2 11.7 9.6 17.1 Np
CRP (mg/l)***** Increase Na Increase Stable Stable Stable Decrease Np
At first detection 6.2 11.1 <1.0 <1.0 3.5 <1.0 19.9 17.9
At end of observation 30.7 Na 11.7 <1.0 5.4 4.1 6.7 Np
*years from first detection to Trichosporon to end of observation period, **change throughout the observation period of the individual patient, decline defined as ΔFEV1 > 1%pred/year, ***change in BMI throughout
the observation period, ****change throughout the observation period, change defined as ΔIgG >3 g/l,, *****change throughout the observation period, change defined as ΔCRP >5 mg/l, + above reference range.
Abbreviations: Na = not available, Nk = not known, np = not possible, chron = chronic, cont = continuous, rep = repeated, / = alternating, w = weeks, y = years, Acinet baum = Acinetobacter baumannii, Acinet
fum = Acinetobacter fumigatus, Asp flav = Aspergillis flavipes, Asp fum = Aspergillus fumigatus, Burc cep = Burkholderia cepacia, Cand alb = Candida albicans, Cand glab = Candida glabrata, Cand paraps = Candida
parapsilosis, Cefu = cefuroxim, Cep = ceporexin, Ceph = cephalexin, Cip = ciprofloxacin, Col = colistin, Cot = cotrimoxazole, E coli = Escherichia coli, Gern = gernebcin, Inqu lin = Inquilinus limosus, Nocard farc = Norcarderia
facrinica, Pet sord = Petriella sordida, Penicill Sp = Penicillium sp, Prot mirab = Proteus mirabilis, Pseudoall boyd = Pseudoallescheria boydii, Ps ae = Pseudomonas aeruginosa, Ps ae muc = Pseudomonas aeruginosa
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The observation period for patient 8 was 0.8 years and
thus not long enough for an analysis of the clinical
course. One patient (4) had only a single positive
respiratory specimen and exhibited a stable FEV1,
stable CRP, IgG and an increase in BMI. The other 6
patients (1,2,3,5,6,7) had repeatedly Trichosporon positive
specimens with a mean detection period of 4.5 years
(range 0.6 – 7.1). FEV1, BMI, CRP and IgG remained
stable in 1, respectively 2 of these patients (2,6) with a
mean detection period of 2.5 years (range 0.6 – 3.9).
FEV1 declined by a mean ΔFEV1 of – 2.9pred%/year
(range −1.1pred%/year to −5.8pred%/year) in 4 patients
(1,3,5,7) with repeated positive samples and a mean
detection period of 5.7 years (range 1.9-7.1). CRP in-
creased in 2 of these patients (1,3) and IgG increased
for 3 of these patients (1, 3, 7), in patient 1 above the
reference range. BMI declined in 2 (1,7) of these patients






































Figure 2 Course of FEV1 (%pred) and the inflammatory marker
IgG (g/l) of CF patients positive for Trichosporon. Mean FEV1 and
IgG values for 7 Trichosporon positive patients with sufficiently long
follow-up periods at 7 time intervals: 1 and 2 years before first
Trichosporon detection, at first detection, 1, 2 and 3 years after first
detection and at the end of the observation period. The mean number
of data points per year was 4 (range 2–7). Each symbol/line represents
one patient. The solid lines represent the patients with a decline in
FEV1. The grey line represents the patient with only a single
Trichosporon positive specimen.Treatment
Patients 3 and 5 received antimycotic treatment due to
an unexplained but marked deterioration of the clinical
status. Patient 5 with a prolonged detection period of
T. mycotoxinivorans exhibited a recurrent and tormenting
dry cough; she reported a substantial subjective improve-
ment of the dry cough after inhalation with nebulized
Amphotericin B (not liposomal, 15 mg 1:1 diluted with
distilled water, 1x/day for 4–8 weeks, 3x/year). T. mycotox-
invorans however persisted in the sputum. Patient 3 is
described in detail below.
Clinical course of patient 3
Until the age of 16 years a female CF patient (ΔF508/
not known) with pancreatic insufficiency had only minor
respiratory symptoms, FEV1 values between 85 and 106
pred% and a BMI between the 3rd to 5th percentile.
Trichosporon spp. was detected for the first time at the
age of 10 years (Figure 3a). Further respiratory pathogens
at first detection of Trichosporon included Stenotrophomo-
nas maltophilia, Staphylococcus aureus, Candida albicans
and Aspergillus fumigatus (Figure 3b). The patient was
treated with standard CF therapy and had no history of
systemic or nebulized steroids. At the age of 16 years, the
stable clinical course was disrupted by 4 severe exacerba-
tions within 12 months requiring intensive treatment
(Figure 3a). The patient exhibited dyspnea, bloody sputum,
an oxygen saturation of 89% in ambient air, night sweats,
and a weight loss of 5 kg. FEV1 dropped to 45 pred%
(Figure 4). Due to the lack of response to intensive i.v.
antibiotic and supportive treatment in the presence of
Trichosporon inkin, i.v. antimycotic treatment with li-
posomal Amphotericin B (4.6 mg/kg/d) was initiated;
nebulized Amphotericin B was not tolerated. Resistance
testing of Trichosporon inkin revealed good effectiveness
of Amphotericin B, Posaconazole and Voriconazole.
After 8 weeks of Amphotericin treatment, the patient’s
condition improved considerably and oral therapy with
Voriconazole was initiated. FEV1 had increased from
45 pred% to 65 pred% (Figure 4). The patient developed
an impaired color vision and Voriconazole was replaced
with Posaconazole, which has been continued since.
12 months later 3 more episodes of clinical deterioration
had been treated with i.v antibiotics and i.v. Amphotericin
B. The clinical status stabilized with FEV1 values between
55 and 70 pred%. The chest x-rays taken 2 months and
2 years after the first exacerbation show the extent of
damage (Figure 5). Trichosporon inkin persists in the
sputum until the current age of 17.8 years.
Discussion
The relevance of fungal colonization in CF patients has
only recently been recognized [22]. Colonization with C.
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Figure 3 Clinical course and colonization with other microorganisms of a patient (3) infected with T. inkin. a: Clinical course: time-points
of exacerbations and therapeutic interventions. b: Colonization with different respiratory microorganisms.
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function and a negative effect on the clinical outcome
[23,24]. A. fumigatus in particular was demonstrated to
have a pro-inflammatory effect on the CF epithelium [25].
However, the available studies are limited by important
confounders, such as the lack of standardized detection
methods or co-infection with other microorganisms. The
contribution of fungi to CF lung disease thus remains
controversial as does the indication to a non-risk free
antifungal therapy.
The prevalence and the relevance of Trichosporon spp.
in CF has to date not been investigated. In the present
study Trichosporon spp. was found in respiratory samplesof 2.2% of the cohort over an eight year period.
Colonization rates of Trichosporon spp. in non-CF
patients range between 0.8% in throat cultures and
3.1% in stool cultures of patients in a large Veterans
hospital [26] and 3.7% in stool, skin or urine of 317
immunosuppressed hosts [27].
Risk factors for colonization and/or infection with
Trichosporon in CF are also unknown. Invasive trichos-
poronosis in non-CF patients has been associated with
mucosal disruption and general immune dysfunction
due to HIV or malignancies [28], however, the exact
pathophysiology of Trichosporon infections is unknown. It
is possible that mucosal disruption in CF also predisposes
2 months after first pulmonary exacerbation 2 years after first pulmonary exacerbation
Figure 5 Chest X-ray of a patient (3) infected with T. inkin two months and two years after first pulmonary exacerbation due to
T. inkin. The second X-ray demonstrates a strong increase in hyperinflation, increasing bronchiectasis and mucus plugging, increasingly thickened























































Figure 4 Course of FEV1 (% pred), CRP (mg/dl) and ESR 1 h (mm) of a patient (3) infected with T. inkin.
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age, prior systemic or inhaled steroid treatment, ABPA
and possibly CF associated diabetes might predispose
for Trichosporon colonization. 3 of 8 patients carried a
stop mutation in addition to dF508, which is higher
than the general frequency of stop mutations in German
CF population (1.8% for R553X; <1% for S466X) [29]. Our
data further indicate that longer Trichosporon detection
periods may be associated with a decline in lung function
and BMI, and increased inflammation. Chronic airway
colonization with Trichosporon may harbour the risk of
clinically relevant infection leading to unstable lung
disease. Further studies will have to corroborate these
findings.
Limitations of the current study include the relatively
small amount of patients, the retrospective design, the
presence of other microorganisms as a confounder and
the lack of specification of all Trichosporon spp. Standard-
ized diagnostic procedures were subsequently introduced.
Up to now three case reports of CF patients have dem-
onstrated the potential of exacerbation and in two cases
of a fatal, disseminated infection due to Trichosporon spp.
[11-13]. Here we add another patient (3) whose course
was significantly affected by infection with T. inkin.
This conclusion is based on the unexplained failure of
intensive antibacterial and supportive therapy and the
clear improvement and stabilization of the clinical status
after the initiation of antifugal therapy. Repeated detection
of Trichosporon spp. may indicate CF patients at risk for
deterioration; preemptive treatment may be considered.
Conclusion
To conclude, emerging pathogens relevant for CF lung
disease may include the basidiomycetous yeast Trichos-
poron. Its detection in respiratory secretions in patients
not responding to standard antimicrobial therapy may
warrant targeted antifungal therapy.
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